No Data
Shanghai Kaibao PharmaceuticalLtd (SZSE:300039) Sheds 5.6% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Shanghai Kaibao: Report for the third quarter of 2024
Shanghai Kaibao Pharmaceutical (300039.SZ): The net income for the first three quarters was 0.217 billion yuan, a year-on-year increase of 10.68%.
Gelonghui on October 24th: shanghai kaibao pharmaceutical (300039.SZ) announced its third quarter report for 2024, with the company achieving revenue of 1.121 billion yuan in the first three quarters, a year-on-year decrease of 2.87%; net income attributable to shareholders of the listed company was 0.217 billion yuan, a year-on-year increase of 10.68%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.212 billion yuan, a year-on-year increase of 11.93%; basic earnings per share was 0.2075 yuan.
Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Market Cap Rose CN¥397m Last Week; Retail Investors Who Hold 56% Profited and so Did Insiders
shanghai kaibao pharmaceutical (300039.SZ): The company's products Phlegm-heat-clearing injection and Phlegm-heat-clearing capsules are currently not being sold in the Hong Kong and Taiwan regions.
GeLonghui September 23rd | shanghai kaibao pharmaceutical (300039.SZ) stated on the investor interaction platform that the company's products Tan Reqing Injection and Tan Reqing Capsules are currently not sold in Hong Kong and Taiwan.
Shanghai Kaibao Pharmaceutical (300039.SZ): Currently, the company does not have any related products for the treatment of monkeypox.
Shanghai Kaibao (300039.SZ) stated on the investor interaction platform on September 23 that the company currently does not have any products for the treatment of monkeypox. The company's main product, Tanreqing Injection, is included in the clinical guidelines or treatment plans for prevention and control of "bird flu", "H1N1 flu", "H7N9 flu", "hand, foot and mouth disease", "dengue fever", "Ebola", "Middle East respiratory syndrome", and "COVID-19" by the National Health Commission and the Traditional Chinese Medicine Administration. In July 2024, the General Office of the National Health Commission issued the "Diagnosis and Treatment Plan for Measles and Other Infectious Diseases (2024 Edition)".
The Market Doesn't Like What It Sees From Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Earnings YetNo Data
No Data
